Unexpected roles for PCSK9 in lipid metabolism

Current Opinion in Lipidology

Volumn 22, Issue 3, 2011, Pages 192-196

  Soutar, Anne K ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Apolipoprotein B; LDL receptor pathway; PCSK9; triglyceride secretion

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; DISEASE SEVERITY; FAMILIAL HYPERCHOLESTEROLEMIA; GAIN OF FUNCTION MUTATION; HEPATOMA CELL; HUMAN; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN SECRETION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPID METABOLISM; LIPOPROTEINS; LIPOPROTEINS, LDL; MUTATION, MISSENSE; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; TRIGLYCERIDES;

MUS; MUS MUSCULUS;

EID: 79957923056     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32834622b5     Document Type: Article

References (23)

1. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007; 4:214-225. (Pubitemid 46502094)
2. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34:154-156. (Pubitemid 36666925)
3. Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein con-vertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 2003; 100:928-933. (Pubitemid 36183932)
4. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009; 50 (Suppl.):S172-S177.
5. Fasano T, Sun XM, Patel DD, Soutar AK. Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells. Atherosclerosis 2009; 203:166-171.
6. Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37:161-165.
7. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:1264-1272.
8. Lambert G, Krempf M, Costet P. PCSK9: a promising therapeutic target for dyslipidemias? Trends Endocrinol Metab 2006; 17:79-81.
9. Labonte P, Begley S, Guevin C, et al. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology 2009; 50:17-24.
10. Naoumova RP, Tosi I, Patel D, et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol 2005; 25:2654-2660. (Pubitemid 43732293)
11. Sun XM, Eden ER, Tosi I, et al. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum Mol Genet 2005; 14:1161-1169. (Pubitemid 40613905)
12. Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006; 43:943-949. (Pubitemid 46080192)
13. Maxwell KN, Breslow JL Adenoviral-mediated expression of PCSK9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA 2004; 101:7100-7105. (Pubitemid 38596449)
14. Park SW, Moon YA, Horton JD. Posttranscriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 2004; 279:50630-50638. (Pubitemid 39577880)
15. Ouguerram K, Chetiveaux M, Zair Y, et al.Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol 2004; 24:1448-1453. (Pubitemid 39050439)
16. Baass A, Dubuc G, Tremblay M, et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009; 55:1637-1645.
17. Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and metabolic determi-nants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009; 94:2537-2543.
18. Chan DC, Hamilton SJ, Rye KA, et al. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients. Diabetes Obes Metab 2010; 12:752-756.
19. Persson L, Cao G, Stahle L, et al. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol 2010; 30:2666-2672.
20. Herbert B, Patel D, Waddington SN, et al. Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control. Arterioscler Thromb Vasc Biol 2010; 30:1333-1339.
21. Blasiole DA, Oler AT, Attie AD. Regulation of apoB secretion by the low density lipoprotein receptor requires exitfrom the endoplasmic reticulum and interaction with apoE or apoB. J Biol Chem 2008; 283:11374-11381.
22. Lalanne F, Lambert G, Amar MJ, et al. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. J Lipid Res 2005; 46:1312-1319. (Pubitemid 43109846)
23. Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006; 116:2995-3005. (Pubitemid 44684484)